Welcome to our dedicated page for Unitedhealth Gp SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UnitedHealth Group Incorporated filings document the formal disclosures of a large health care company organized around UnitedHealthcare and Optum. Proxy materials describe board governance, executive compensation, shareholder voting matters and the company’s complementary businesses: UnitedHealthcare health coverage and Optum clinical, data, product, pharmacy and care services.
Current reports on Form 8-K cover operating and financial results, Regulation FD communications, strategy and market-position discussions, director appointments, compensation arrangements and other material-event disclosures. The filing record also documents governance practices, capital-structure and compensation matters, risk-related business context and the regulatory reporting framework for a Delaware public operating company in the health care sector.
UnitedHealth Group Incorporated has appointed Dennis Stankiewicz, age 48, as Chief Accounting Officer effective March 2, 2026. He will also continue serving as Corporate Controller, a role he has held since April 17, 2023, after joining the company in 2016 as General Auditor.
His compensation includes a $550,000 annual base salary, an initial annual cash bonus target of 85% of base salary, and eligibility for annual and long-term stock-based awards consistent with his seniority. He will receive severance equal to one times base salary if terminated without cause, conditioned on a non-compete during the severance period. The company states he has no related-party transactions requiring disclosure, while current Chief Accounting Officer Tom Roos will become Chief Financial Officer of Optum Insight on March 2, 2026.
UnitedHealth Group is a large, diversified health care and well-being company built around two complementary businesses: Optum and UnitedHealthcare. It is listed on the New York Stock Exchange under the symbol UNH and had 907,675,839 common shares outstanding as of February 20, 2026.
Optum combines Optum Health, Optum Insight and Optum Rx, delivering value-based care, analytics and pharmacy services. In 2025, Optum Rx managed $188 billion in pharmaceutical spending, while Optum Insight reported an aggregate backlog of $31.1 billion, with $18.3 billion expected within 12 months.
UnitedHealthcare provides health benefits to employers, individuals, Medicare and Medicaid beneficiaries, serving tens of millions of people across its Employer & Individual, Medicare & Retirement and Community & State lines. Premium revenues from risk-based products represent nearly 80% of total consolidated revenues, and CMS premium revenues account for 44%. The company employs more than 390,000 people, including nearly 165,000 clinical professionals, and operates under extensive U.S. and international health care, privacy, banking and consumer protection regulations, with detailed risk factors around medical cost trends, technology, cyber security, regulation and competition.
UNITEDHEALTH GROUP INC Chief Accounting Officer Thomas E. Roos reported several equity-related transactions on common stock and options. He was granted 9,768 non-qualified stock options with an exercise right to buy shares, all recorded at a price of $0.0000 per option. He also acquired 2,436 shares of common stock through a grant or award and had 151.777 shares of common stock disposed of to cover tax obligations at $282.3400 per share. Following these transactions, his directly held common stock position increased to 31,283.641 shares. The non-qualified stock options vest 25% each year on February 23 from 2027 through 2030, and restricted stock units referenced in the footnotes vest on the same schedule.
UNITEDHEALTH GROUP INC executive Christopher R. Zaetta, EVP & Chief Legal Officer, reported multiple equity compensation transactions. He received a grant of 28,414 non-qualified stock options, each giving a right to buy UnitedHealth common shares, with the options vesting 25% annually on February 23 from 2027 through 2030.
Zaetta also acquired 7,084 shares of common stock as a grant, described in the footnotes as restricted stock units that vest 25% each year on February 23 from 2027 through 2030. In a related tax-withholding disposition, 129.454 shares of common stock were withheld at $282.34 per share to cover tax obligations, reducing the directly held common stock balance to 9,542.54 shares while increasing total equity awards outstanding.
UNITEDHEALTH GROUP INC executive Timothy John Noel reported new equity awards and a small tax-related share disposition. He received 35,517 non-qualified stock options and 8,855 shares of common stock as grants. The options and the related restricted stock units vest 25% each year on February 23 from 2027 through 2030. To satisfy tax obligations, 123.171 shares of common stock were disposed of at $282.34 per share, leaving him with 17,472.324 common shares directly owned.
UNITEDHEALTH GROUP executive Erin McSweeney reported new equity awards and a related tax share disposition. She was granted 19,535 non-qualified stock options with an exercise right, and 4,871 shares of common stock as a stock award. The filing also shows 130.684 shares of common stock were disposed of at $282.34 per share to satisfy tax withholding obligations. Both the restricted stock units referenced in the footnotes and the non-qualified stock options vest 25% each year on February 23 from 2027 through 2030, spreading the compensation over four years.
UNITEDHEALTH GROUP INC executive Patrick Hugh Conway, Chief Executive Officer of Optum, reported equity compensation and a related tax share disposition. He was granted 35,517 non-qualified stock options with an exercise right to buy shares, and 8,855 shares of common stock as a stock award. Both awards vest in four equal installments of 25% on February 23 of each year from 2027 through 2030. To satisfy tax obligations on equity, 178.988 shares of common stock were disposed of at $282.34 per share, leaving him with 18,479.97 common shares held directly after these transactions.
DeVeydt Wayne S reported acquisition or exercise transactions in this Form 4 filing.
UnitedHealth Group’s Chief Financial Officer Wayne S. DeVeydt reported equity awards that increase his direct ownership in the company. He was granted non-qualified stock options for 35,517 shares on February 23, 2026, and a separate award of 8,855 shares of common stock at $282.34 per share.
The common stock award and related restricted stock units vest in 25% increments each February 23 from 2027 through 2030. The stock options follow the same vesting schedule, also vesting 25% annually on those dates. These awards are classified as grants or awards rather than open-market purchases.
UnitedHealth Group updated the terms of a stock option previously granted to Stephen Hemsley. The grant, originally issued on May 14, 2025 with three-year cliff vesting, now carries a two-year share holding requirement after vesting.
Hemsley must hold any net shares obtained from exercising this option until May 14, 2030, reinforcing longer-term alignment with shareholders. The only exceptions are in cases of death or disability, and all other terms of the stock option remain unchanged.
UnitedHealth Group executive Erin McSweeney reported two insider transactions involving company common stock. On February 20, 2026, she disposed of 136.641 shares and 155.182 shares at $290.00 per share, both coded as F transactions, meaning shares were withheld to cover tax liabilities rather than sold on the open market.